Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

ConclusionsThe combination of belinostat 2000  mg/m2 days 1 –5 and 13-cRA 100 mg/m2 days 1 –14, every 21 days, was well-tolerated and an MTD was not reached despite doubling the established single-agent MTD of belinostat.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research